Abstract
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has shown promise for patients with relapsed or refractory multiple myeloma (RRMM), yet its use is often complicated by adverse events such as cytokine release syndrome and hematologic toxicities. This study evaluates the prognostic significance of spleen size, measured via computed tomography (CT), in predicting clinical outcomes for RRMM patients undergoing CAR T-cell therapy. We retrospectively analyzed data from patients treated with Idecabtagene vicleucel or Ciltacabtagen autoleucel (N=73) and show that enlarged spleen size is associated with severe and prolonged thrombocytopenia, higher metabolic tumor volumes, and elevated soluble BCMA (sBCMA) levels. Our findings indicate that splenomegaly (>340 cm³) is an independent prognostic marker for both progression-free and overall survival, outperforming markers such as sBCMA levels, EASIX, and CAR- Hematotox scores. These results suggest that spleen size could enhance risk stratification in CAR T-cell therapy for RRMM patients, offering a readily accessible tool for guiding monitoring strategies and healthcare resource management.
Competing Interest Statement
GNF received honoraria from Novartis Pharma GmbH, Germany, Incyte Biosciences GmbH, Germany, and Pfizer, Germany, outside the submitted work. KM received grants and personal fees from AbbVie and personal fees from Bristol Myers Squibb, Astellas, Janssen, Novartis, Otsuka, Pfizer, Menarini StemLine, and Servier, outside the submitted work. UP received honoraria from Celgene/Jazz, AbbVie, Curis, Geron, and Janssen; consulting or advisory roles with Celgene/Jazz, Novartis, and BMS GmbH & Co KG; and research funding from Amgen (institutional), Janssen (institutional), Novartis (institutional), BerGenBio (institutional), Celgene (institutional), and Curis (institutional). UP is also a co-inventor of a patent for a TFR-2 antibody (Rauner et al., Nature Metabolics, 2019) and reported travel, accommodations, and expenses from Celgene. VV received honoraria from Janssen, BMS GmbH & Co KG, Gilead Sciences, and Amgen; consulting or advisory roles with Gilead Sciences, Janssen, BMS GmbH & Co KG, and Amgen; and travel, accommodations, and expenses from Sobi, Janssen, Gilead Sciences, and Amgen. MM received honoraria from Janssen, BMS GmbH & Co KG, Amgen, AbbVie, Stemline Therapeutics, Takeda, Sanofi, and Pfizer; consulting or advisory roles with Janssen, BMS GmbH & Co KG, Pfizer, and Sanofi; and research funding from Janssen, SpringWorks Therapeutics, and Roche/Genentech. MM also reported travel, accommodations, and expenses from Janssen, Stemline Therapeutics, and Pfizer. TW, MF, JA, VS, DF, NG, LF, HW, SYW, MJ, CH, MH, SH, TD, KR, TN, and HJM declare no conflict of interest.
Funding Statement
This work was funded by grants from the International Myeloma Society (IMS Research Grant 2023) and the German Research Foundation (SPP ubone) and EU HORIZON (CERTAINTY). The CERTAINTY project is funded by the European Union (Grant Agreement 101136379). The authors acknowledge the financial support by the Federal Ministry of Education and Research of Germany and by Saechsisches Staatsministerium fuer Wissenschaft, Kultur und Tourismus in the programme Center of Excellence for AI-research "Center for Scalable Data Analytics and Artificial Intelligence Dresden/Leipzig", project identification number: ScaDS.AI
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University of Leipzig gave ethical approval for this work (361/22-ek).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
